Quest Diagnostics Raises Full-Year Outlook After Strong Second Quarter

Quest Diagnostics reported a 10.2% revenue increase to $3.04 billion for the second quarter of 2026, fueled by robust organic growth across its physician and hospital channels. Following the results, the Secaucus-based diagnostic firm raised its full-year revenue and earnings guidance, citing sustained demand for its testing services.

Today, 13:49· Corp and Tech· 537 reads

The company’s adjusted diluted earnings per share climbed to $3.12, a 19.1% increase compared to the same period last year. Driven by this performance, Quest now anticipates full-year 2026 revenues between $11.95 billion and $12.05 billion, up from its previous forecast. Adjusted diluted EPS for the year is now projected to land between $11.05 and $11.25.

CEO Jim Davis attributed the gains to the company’s focus on integrating innovative testing into clinical workflows. Recent operational milestones include the expansion of the Haystack MRD test in New York and new collaborations in kidney care with Fresenius Medical Care. Looking ahead, the firm continues to prioritize automation in its labs to improve diagnostic quality and specimen processing efficiency.

Quest Diagnostics Raises Full-Year Outlook After Strong Second Quarter

Comments (0)